18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax

J Nucl Med. 2003 Apr;44(4):540-8.

Abstract

Recent reports have indicated the value and limitations of (18)F-FDG PET and (201)Tl SPECT for determination of malignancy. We prospectively assessed and compared the usefulness of these scintigraphic examinations as well as (18)F-FDG PET delayed imaging for the evaluation of thoracic abnormalities.

Methods: Eighty patients with thoracic nodular lesions seen on chest CT images were examined using early and delayed (18)F-FDG PET and (201)Tl-SPECT imaging within 1 wk of each study. The results of (18)F-FDG PET and (201)Tl SPECT were evaluated and compared with the histopathologic diagnosis.

Results: Fifty of the lesions were histologically confirmed to be malignant, whereas 30 were benign. On (18)F-FDG PET, all malignant lesions showed higher standardized uptake value (SUV) levels at 3 than at 1 h, and benign lesions revealed the opposite results. Correlations were seen between (18)F-FDG PET imaging and the degree of cell differentiation in malignant tumors. No significant difference in accuracy was found between (18)F-FDG PET single-time-point imaging and (201)Tl SPECT for the differentiation of malignant and benign thoracic lesions. However, the retention index (RI) of (18)F-FDG PET (RI-SUV) significantly improved the accuracy of thoracic lesion diagnosis. Furthermore, (18)F-FDG PET delayed imaging measuring RI-SUV metastasis was useful for diagnosing nodal involvement and it improved the specificity of mediastinal staging.

Conclusion: No significant difference was found between (18)F-FDG PET single-time-point imaging and (201)Tl SPECT for the differentiation of malignant and benign thoracic lesions. The RI calculated by (18)F-FDG PET delayed imaging provided more accurate diagnoses of lung cancer.

Publication types

  • Clinical Trial
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Diagnosis, Differential
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Lung Neoplasms / classification
  • Lung Neoplasms / diagnostic imaging
  • Male
  • Mediastinal Diseases / classification
  • Mediastinal Diseases / diagnostic imaging
  • Mediastinal Diseases / metabolism
  • Mediastinal Neoplasms / classification
  • Mediastinal Neoplasms / diagnostic imaging*
  • Mediastinal Neoplasms / metabolism
  • Middle Aged
  • Neoplasm Staging / methods
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Statistics as Topic
  • Thallium* / pharmacokinetics
  • Tomography, Emission-Computed / methods*
  • Tomography, Emission-Computed, Single-Photon / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • thallium chloride
  • Thallium